Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Subcutaneous nemolizumab eases itching for atopic dermatitis

Publish date:: July 13, 2020

Key clinical point: Subcutaneous nemolizumab significantly improved pruritus in atopic dermatitis patients who were resistant to topical treatments.

Major finding: The average change in visual analog scale Score was –42.8% for nemolizumab patients and –21.4% for placebo patients.

Study details: The data come from a phase 3, randomized trial of 143 Japanese adults with atopic dermatitis.

Disclosures: The study was supported by Maruho. Dr. Kabashima disclosed consulting fees from Maruho and two coauthors were Maruho employees.

Citation:

Kabashima K et al. N Engl J Med. 2020 Jul 9. doi: 10.1056/NEJMoa1917006.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Dermatology

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

Study results support screening rosacea patients for cardiometabolic disease,

No lab monitoring needed in adolescents on dupilumab,